OxfordBiomedica |

AAV platform

We work across key viral vector delivery systems including adeno-associated virus (AAV) to provide innovative solutions to cell and gene therapy biotechnology and biopharma companies.

LentiVector^® platform

We have built a sector leading lentiviral delivery system, LentiVector^® platform which is already used in commercially available treatments.

Overview

Discover Oxford Biomedica - a leading gene and cell therapy with over 25 years of experience.

Get in touch

Contact form

Press releases

Oxford Biomedica Solutions announces novel Dual Plasmid Transfection System, and has demonstrated suspension bioreactor titers above E15 vg/L, and chromatography purification achieving 90% fully in-tact vector

06 May 2022

2021 Annual report and accounts & AGM notification

27 April 2022

Preliminary results for the year ended 31 December 2021

20 April 2022

Oxford Biomedica Appoints Namrata P Patel as Non-Executive Director

13 April 2022

Platform

Our viral vector platform is enabling our customers to bring next generation treatments for serious diseases to market.

Services

OXB is an innovative leading viral vector specialist – Lenti, AAV, Adeno and beyond - focused on delivering life changing therapies to patients.

InvestorsGo

PipelineGo